| The Top 3 Stock Picks at the World's Greatest Hedge Fund |
A reclusive firm is often considered the world's most successful hedge fund. That company is Renaissance Technologies. |
marketbeat.com |
2025-05-02 11:16:58 |
Czytaj oryginał (ang.) |
| UTHR Q1 Earnings & Revenues Beat Estimates on Higher Tyvaso Sales |
United Therapeutics reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven mainly by strong Tyvaso sales. |
zacks.com |
2025-05-01 13:00:51 |
Czytaj oryginał (ang.) |
| United Therapeutics Corporation (UTHR) Q1 2025 Earnings Call Transcript |
United Therapeutics Corporation (NASDAQ:UTHR ) Q1 2025 Earnings Conference Call April 30, 2025 9:00 AM ET Company Participants Dewey Steadman - Head of Investor Relations Martine Rothblatt - Chairperson & Chief Executive Officer Michael Benkowitz - President & Chief Operating Officer Leigh Peterson - Executive Vice President, Product Development and Xenotransplantation James Edgemond - Chief Financial Officer & Treasurer Conference Call Participants Joseph Thome - TD Cowen Jessica Fye - JPMorgan Roanna Ruiz - Leerink Andreas Argyrides - Oppenheimer Roger Song - Jefferies Ash Verma - UBS Operator Good morning and welcome to the United Therapeutics Corporation First Quarter 2025 Corporate Update. My name is Dorwin [ph] and I will be your conference operator today. |
seekingalpha.com |
2025-04-30 17:09:08 |
Czytaj oryginał (ang.) |
| United Therapeutics (UTHR) Reports Q1 Earnings: What Key Metrics Have to Say |
While the top- and bottom-line numbers for United Therapeutics (UTHR) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-04-30 14:35:59 |
Czytaj oryginał (ang.) |
| United Therapeutics (UTHR) Q1 Earnings and Revenues Top Estimates |
United Therapeutics (UTHR) came out with quarterly earnings of $6.63 per share, beating the Zacks Consensus Estimate of $6.29 per share. This compares to earnings of $6.17 per share a year ago. |
zacks.com |
2025-04-30 12:35:35 |
Czytaj oryginał (ang.) |
| United Therapeutics Corporation Reports First Quarter 2025 Financial Results |
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2025. Total revenues in the first quarter of 2025 grew 17 percent year-over-year to $794.4 million, compared to $677.7 million in the first quarter of 2024. “2025 is off to a tremendous start as we reported yet another quarter of record revenue,” said Martine Rothblatt, Ph.D., Chair. |
businesswire.com |
2025-04-30 10:30:00 |
Czytaj oryginał (ang.) |
| United Therapeutics (UTHR) Earnings Expected to Grow: Should You Buy? |
United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-23 15:05:37 |
Czytaj oryginał (ang.) |
| Here's Why United Therapeutics (UTHR) is a Strong Value Stock |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-04-11 14:46:12 |
Czytaj oryginał (ang.) |
| These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar |
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now. |
zacks.com |
2025-04-11 13:55:34 |
Czytaj oryginał (ang.) |
| Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report? |
United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. |
zacks.com |
2025-04-08 17:15:40 |
Czytaj oryginał (ang.) |
| United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the International Society for Heart and Lung Transplantation 45th Annual Meeting and Scientific Sessions |
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that ten posters and presentations across its commercial and development portfolio will be presented at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting and Scientific Sessions taking place April 27 through April 30, 2025 in Boston. “The additional data across our portfolio presented at this year. |
businesswire.com |
2025-04-04 11:00:00 |
Czytaj oryginał (ang.) |
| United Therapeutics: Don't Fear The Patent Expiration Too Much |
United Therapeutics is rated as a BUY due to high financial growth, positive long-term outlook, and current undervaluation despite patent expiration concerns. The company's revenue is heavily reliant on Treprostinil-based drugs, with Tyvaso being the highest revenue generator, facing competition from Liquidia Corporation post-2025. UTHR shows strong financial metrics: 5Y revenue CAGR of 14.47%, net income CAGR of 20.41%, and FCF CAGR of 16.20%, with almost no debt. |
seekingalpha.com |
2025-03-29 10:17:15 |
Czytaj oryginał (ang.) |
| United Therapeutics Corporation (UTHR) Q4 2024 Earnings Call Transcript |
Start Time: 09:00 January 1, 0000 9:31 AM ET United Therapeutics Corporation (NASDAQ:UTHR ) Q4 2024 Earnings Conference Call February 26, 2025, 09:00 AM ET Company Participants Martine Rothblatt - Chairperson and CEO Michael Benkowitz - President and COO James Edgemond - CFO and Treasurer Leigh Peterson - EVP, Product Development and Xenotransplantation Pat Poisson - EVP, Technical Operations Dewey Steadman - Head, IR Conference Call Participants Roger Song - Jefferies Jessica Fye - JPMorgan Ash Verma - UBS Joseph Thome - TD Cowen Roanna Ruiz - Leerink Andreas Argyrides - Oppenheimer Operator Good morning, and welcome to the United Therapeutics Corporation Fourth Quarter 2024 Corporate Update. My name is Cindy, and I will be your conference operator today. |
seekingalpha.com |
2025-02-26 16:14:04 |
Czytaj oryginał (ang.) |
| United Therapeutics Stock Down Despite Q4 Earnings & Sales Beat |
UTHR beats fourth-quarter estimates for both earnings and sales. Tyvaso sales fall short of estimates. |
zacks.com |
2025-02-26 14:00:42 |
Czytaj oryginał (ang.) |
| United Therapeutics (UTHR) Surpasses Q4 Earnings and Revenue Estimates |
United Therapeutics (UTHR) came out with quarterly earnings of $6.19 per share, beating the Zacks Consensus Estimate of $6.10 per share. This compares to earnings of $4.36 per share a year ago. |
zacks.com |
2025-02-26 10:35:23 |
Czytaj oryginał (ang.) |
| United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results |
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2024. Full year 2024 revenues rose to a record $2.88 billion, reflecting 24% growth over 2023. “I want to congratulate every Unitherian for their relentless dedication, which has allowed us to deliver a third consecutive year of record revenue,” said Martine Rothblatt, P. |
businesswire.com |
2025-02-26 08:30:00 |
Czytaj oryginał (ang.) |
| United Therapeutics: A Unique Business With High Margins And Expansion Potential |
United Therapeutics is highly undervalued with a P/E of 16x and EV/EBITDA of 8.64x, compared to sector medians of 28x and 15.15x, respectively. The company shows strong revenue growth, driven by Tyvaso (+33% YoY), and maintains high margins and low debt burden, with a 39% growth potential. Key growth drivers include Tyvaso's expansion into IPF, Ralinepag development, xenotransplantation breakthroughs, and international market expansion. |
seekingalpha.com |
2025-02-25 03:06:44 |
Czytaj oryginał (ang.) |
| Seeking Clues to United Therapeutics (UTHR) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics |
Besides Wall Street's top -and-bottom-line estimates for United Therapeutics (UTHR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024. |
zacks.com |
2025-02-24 12:21:57 |
Czytaj oryginał (ang.) |
| Strength Seen in United Therapeutics (UTHR): Can Its 4.9% Jump Turn into More Strength? |
United Therapeutics (UTHR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road. |
zacks.com |
2025-02-13 13:16:16 |
Czytaj oryginał (ang.) |
| UTHR or ZTS: Which Is the Better Value Stock Right Now? |
Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now? |
zacks.com |
2025-02-07 14:41:21 |
Czytaj oryginał (ang.) |
| Why Investors Need to Take Advantage of These 2 Medical Stocks Now |
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP. |
zacks.com |
2025-02-05 11:51:27 |
Czytaj oryginał (ang.) |
| United Therapeutics Corporation Announces FDA Clearance of its Investigational New Drug Application for the UKidney Xenotransplantation Clinical Trial |
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug application (IND) to initiate a clinical study of the company's investigational UKidney™ derived from a 10 gene-edited source pig. The study will enroll an initial cohort of six end-stage renal disease (ESRD) patients, expanding to up to 50 partic. |
businesswire.com |
2025-02-03 09:00:00 |
Czytaj oryginał (ang.) |
| Here's Why United Therapeutics (UTHR) is a Strong Growth Stock |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-01-10 13:01:44 |
Czytaj oryginał (ang.) |
| Are Medical Stocks Lagging United Therapeutics (UTHR) This Year? |
Here is how United Therapeutics (UTHR) and AnaptysBio, Inc. (ANAB) have performed compared to their sector so far this year. |
zacks.com |
2025-01-09 12:46:47 |
Czytaj oryginał (ang.) |
| Here's Why United Therapeutics (UTHR) is a Strong Value Stock |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-01-09 12:46:26 |
Czytaj oryginał (ang.) |
| UTHR vs. STVN: Which Stock Is the Better Value Option? |
Investors interested in stocks from the Medical - Drugs sector have probably already heard of United Therapeutics (UTHR) and Stevanato Group (STVN). But which of these two stocks is more attractive to value investors? |
zacks.com |
2025-01-08 14:55:48 |
Czytaj oryginał (ang.) |
| United Therapeutics Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, will provide an overview and update on the company's business during a presentation at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will take place on Monday, January 13, 2025, from 2:15 p.m. to 2:55 p.m., Pacific Standard Time,. |
businesswire.com |
2025-01-06 09:00:00 |
Czytaj oryginał (ang.) |
| The Zen Ten - My Top Picks For 2025 |
I've been publishing the Zen Ten list since 2008, consistently beating the market by an average of 9.1% per year since 2000. My methodology involves a rigorous three-step screening process using Zacks Investment Research, LSEG StarMine, and StockRover, narrowing 8,000 stocks to just 10. The screening process focuses on earnings growth, value, quality, financial stability, profitability, sustainability, and margin of safety, ensuring a diversified and robust selection. |
seekingalpha.com |
2024-12-29 18:25:01 |
Czytaj oryginał (ang.) |
| Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-12-25 12:51:16 |
Czytaj oryginał (ang.) |
| Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-12-23 12:46:35 |
Czytaj oryginał (ang.) |
| Why Is United Therapeutics (UTHR) Up 1.1% Since Last Earnings Report? |
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-11-29 14:36:18 |
Czytaj oryginał (ang.) |
| United Therapeutics: Competitive Advantages At Such Cheap Multiples Scream Buy |
UTHR's competitive advantages, including high returns on capital and successfully recycling of profits, support a bullish outlook. United Therapeutics' Q3 FY '24 earnings showed strong growth across major product lines, with Tyvaso, Orenitram, and Unituxin all posting significant YoY increases. My numbers project a 40% growth in earnings power for the business over the coming 2-3 years. |
seekingalpha.com |
2024-11-15 20:27:59 |
Czytaj oryginał (ang.) |
| United Therapeutics Expands Into Organ Transplants, But Tyvaso's Legal Battles Loom |
Despite legal challenges and exclusivity risks, United Therapeutics is a leader in PAH treatments, with Tyvaso being the primary revenue driver. UTHR is innovating in organ transplantation and bioengineered organs, including xenotransplantation and ex vivo lung perfusion, which could revolutionize the market. Legal battles, particularly with Liquidia, threaten United Therapeutics' intellectual property, affecting its Tyvaso franchise and competitive position in PAH. |
seekingalpha.com |
2024-11-15 09:00:00 |
Czytaj oryginał (ang.) |
| United Therapeutics: One To Believe In Despite Competitive Threats |
United Therapeutics Corporation's stock has surged over 300% since my 2020 “Buy” rating, driven by strong sales of Tyvaso DPI and other PAH treatments. Despite facing generic competition, United has maintained resilience, leveraging strategic litigation and innovative product development to protect and grow its revenue streams. United's future growth hinges on expanding Tyvaso DPI's market and advancing its pipeline, including promising IPF treatments and groundbreaking organ transplant technologies. |
seekingalpha.com |
2024-11-14 19:16:39 |
Czytaj oryginał (ang.) |
| United Therapeutics Corporation to Present at the UBS Global Healthcare Conference |
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Patrick Poisson, Executive Vice President, Technical Operations, will provide an overview and update on the company's operations during a fireside chat session at the UBS Global Healthcare Conference in Rancho Palos Verdes, CA. The session will take place on Tuesday, November 12, 2024, from 2:45 p.m. to 3:20 p.m., Pacific Standard. |
businesswire.com |
2024-11-05 18:30:00 |
Czytaj oryginał (ang.) |
| United Therapeutics (UTHR) is a Top-Ranked Growth Stock: Should You Buy? |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-11-05 12:45:26 |
Czytaj oryginał (ang.) |
| United Therapeutics (UTHR) is a Top-Ranked Value Stock: Should You Buy? |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-11-04 12:45:43 |
Czytaj oryginał (ang.) |
| United Therapeutics Q3 Earnings & Sales Beat Estimates |
UTHR reports better-than-expected results in third-quarter 2024 on the back of strong demand for its treprostinil medications, especially Tyvaso. |
zacks.com |
2024-11-01 13:20:31 |
Czytaj oryginał (ang.) |
| United Therapeutics Corporation (UTHR) Q3 2024 Earnings Call Transcript |
United Therapeutics Corporation (NASDAQ:UTHR ) Q3 2024 Earnings Conference Call October 30, 2024 9:00 AM ET Company Participants Dewey Steadman - Head of Investor Relations Martine Rothblatt - Chairperson & Chief Executive Officer Michael Benkowitz - President & Chief Operating Officer James Edgemond - Chief Financial Officer & Treasurer Leigh Peterson - Executive Vice President-Product Development & Xenotransplantation Conference Call Participants Joseph Thome - TD Cowen Roanna Ruiz - Leerink Partners Andreas Argyrides - Oppenheimer Roger Song - Jefferies Jessica Fye - JPMorgan Ash Verma - UBS Operator Good morning, and welcome to the United Therapeutics Corporation Third Quarter 2024 Earnings Webcast. My name is Dave, and I will be your conference operator today. |
seekingalpha.com |
2024-10-30 17:09:05 |
Czytaj oryginał (ang.) |
| Here's What Key Metrics Tell Us About United Therapeutics (UTHR) Q3 Earnings |
Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2024-10-30 12:35:53 |
Czytaj oryginał (ang.) |
| United Therapeutics (UTHR) Q3 Earnings and Revenues Top Estimates |
United Therapeutics (UTHR) came out with quarterly earnings of $6.39 per share, beating the Zacks Consensus Estimate of $6.18 per share. This compares to earnings of $5.38 per share a year ago. |
zacks.com |
2024-10-30 10:41:12 |
Czytaj oryginał (ang.) |
| United Therapeutics Corporation Reports Third Quarter 2024 Financial Results |
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2024. Total revenues in the third quarter of 2024 grew 23 percent year-over-year to $748.9 million, compared to $609.4 million in the third quarter of 2023. "I'm proud of the close to 1,300 Unitherians who have contributed to yet another record revenue quarter and reaching a $3. |
businesswire.com |
2024-10-30 08:30:00 |
Czytaj oryginał (ang.) |
| Curious about United Therapeutics (UTHR) Q3 Performance? Explore Wall Street Estimates for Key Metrics |
Beyond analysts' top -and-bottom-line estimates for United Therapeutics (UTHR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024. |
zacks.com |
2024-10-29 12:21:32 |
Czytaj oryginał (ang.) |
| United Therapeutics Corporation to Report Third Quarter 2024 Financial Results Before the Market Opens on Wednesday, October 30, 2024 |
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its third quarter 2024 financial results before the market opens on Wednesday, October 30, 2024. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, October 30, 2024, at 9:00 a.m. Eastern Time. The webcast will be accessible via. |
businesswire.com |
2024-10-23 10:30:00 |
Czytaj oryginał (ang.) |
| United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting |
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that five presentations and one poster across its commercial and development portfolio will be presented at the CHEST 2024 Annual Meeting hosted by the American College of Chest Physicians taking place October 6-9, 2024, in Boston. United Therapeutics will sponsor the Tyvaso DPI®: Clinical Pearls and Drug-Device Characteristics Symposi. |
businesswire.com |
2024-09-24 11:00:00 |
Czytaj oryginał (ang.) |
| United Therapeutics (UTHR) Up 9.9% Since Last Earnings Report: Can It Continue? |
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-08-30 16:36:18 |
Czytaj oryginał (ang.) |
| United Therapeutics Shares Thrive |
Revenue growth and a recent regulatory win are driving shares of United Therapeutics Corporation (UTHR) upward. |
fxempire.com |
2024-08-30 16:02:56 |
Czytaj oryginał (ang.) |